Search clinical trials for: LMI070

Total 3 results

Novartis Pharmaceuticals

Completed

A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease (VIBRANT-HD)

Early Manifest Huntington Disease

Canada, Germany, France, Spain, Hungary
Novartis Pharmaceuticals

Terminated

Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric and Adult Branaplam Formulation in Healthy Adults and the Effect of Food on the Latter.

Healthy Volunteers

United Kingdom
Novartis Pharmaceuticals

Completed

An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)

Spinal Muscular Atrophy

Belgium, Germany, Italy, Russian Federation, Poland, Bulgaria, Denmark

3

Subscribe